Lipodystrophy syndrome in HIV infection. What is it, what causes it and how can it be managed?

Drug Safety

Volumn 23, Issue 1, 2000, Pages 57-76

  Behrens, Georg M N ^a   Stoll, Matthias ^a   Schmidt, Reinhold E ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN B; APOLIPOPROTEIN E; CYTOKINE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GLUCOSE; HUMAN GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LAMIN A; LAMIN C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NELFINAVIR; NUCLEOSIDE ANALOG; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TROGLITAZONE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTHRALGIA; ATHEROSCLEROSIS; BODY BUILD; BODY FAT; DIAGNOSTIC APPROACH ROUTE; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DYSLIPIDEMIA; EDEMA; GASTROINTESTINAL SYMPTOM; GLUCOSE HOMEOSTASIS; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIPODYSTROPHY; LIPOMATOSIS; LIPOSUCTION; NEPHROLITHIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; RASH; REVIEW; RISK FACTOR; THROMBOCYTOPENIA; VERTIGO;

EID: 0033933880     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200023010-00004     Document Type: Review

References (163)

1. 1. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352: 1725-30
2. 2. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbiditiy and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60
3. 3. Flexner C. HIV-protease inhibitors. N Engl J Med 1998; 338: 1281-92
4. 4. Behrens G, Schmidt H, Meyer D, et al. E Vascular complications associated with use of HIV protease inhibitors [letter]. Lancet 1998; 351 (9120): 1958
5. 5. Darvay A, Acland K, Lynn W, et al. Striae formation in two HIV-positive persons receiving protease inhibitors. J Am Acad Dermatol 1999; 41 (3): 467-9
6. 6. Behrens G, Knuth C, Schedel I, et al. Highly active antiretroviral therapy [letter]. Lancet 1998; 351: 1057-8
7. 7. Carr A, Cooper DA. Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor [letter]. N Engl J Med 1998; 339 (18): 1296
8. 8. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12 (7): 51F-8F
9. 9. Wurtz R. Abnormal fat distribution and use of protease inhibitors [letter]. Lancet 1998; 351 (9117): 1735-6
10. 10. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13: 1659-67
11. 11. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIOCO study. AIDS 2000; 14: 37-49
12. 12. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999; 13: 2493-505
13. 13. Striker R, Conlin D, Marx M, et al. Localized adipose tissue hypertrophy in patients receiving human immunodeficiency virus protease inhibitors. Clin Infect Dis 1998 Jul; 27 (1): 218-20
14. 14. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351 (9106): 871-5
15. 15. Miller KK, Daly PA, Sentochnik D, et al. Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 27 (1): 68-72
16. 16. Lo JC, Mulligan K, Tai VW, et al. 'Buffalo hump' in men with HIV-1 infection. Lancet 1998; 351 (9106): 867-70
17. 17. Ho TT, Chan KC, Wong KH, et al. Abnormal fat distribution and use of protease inhibitors. Lancet 1998; 351 (9117): 1736-7
18. 18. Shaw AJ, McLean KA, Evans BA. Disorders of fat distribution in HIV infection. Int J Std Aids 1998; 9 (10): 595-9
19. 19. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998; 12 (6): 37F-9F
20. 20. Dong KL, Bausserman LL, Flynn MM, et al. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr 1999; 21 (2): 107-13
21. 21. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999; 13 (4): 465-71
22. 22. Herry I, Bernard L, de Truchid P, et al. Hypertrophy of the breasts in a patient treated with indinavir. Clin Infect Dis 1997; 25: 937-8
23. 23. Lui A, Karter D, Turett G. Another case of breast hypertrophy in a patient treated with indinavir [letter]. Clin Infect Dis 1998; 26; 1482
24. 24. Donovan B, Bodsworth NJ, Mulhall BP, et al. Gynaecomastia associated with saquinavir therapy. Int J Std Aids 1999; 10 (1): 49-50
25. 25. Schurmann D, Bergmann F, Ehrenstein T, et al. Gynaecomastia in a male patient during protease inhibitor treatment for acute HIV disease [letter]. AIDS 1998; 12 (16): 2232-3
26. 26. Spenatto N, Viraben R. Early lipodystrophy occurring during post-exposure prophylaxis [letter]. Sex Transm Infect 1998; 74 (6): 455
27. 27. Babl FE, Regan AM, Pelton SI. Abnormal body-fat distribution in HIV-1-infected children on antiretrovirals. Lancet 1999; 353 (9160): 1243-4
28. 28. Silva M, Skolnik PR, Gorbach SL, et al. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 1998; 12 (13): 1645-51
29. 29. Stricker RB, Goldberg B. Weight gain associated with protease inhibitor therapy in HIV-infected patients. Res Virol 1998; 149 (2): 123-6
30. 30. Schwenk A, Kremer G, Cornely O, et al. Body weight changes with protease inhibitor treatment in undernourished HIV-infected patients. Nutrition 1999; 15 (6): 453-7
31. 31. Carbonnel F, Maslo C, Beaugerie L, et al. Effect of indinavir on HIV-related wasting. AIDS 1998; 12 (14): 1777-84
32. 32. Pernerstorfer-Schoen H, Schindler K, Parschalk B, et al. Beneficial effects of protease inhibitors on body composition and energy expenditure: a comparison between HIV-infected and AIDS patients. AIDS 1999; 13: 2389-96
33. 33. Shevitz AH, Knox TA, Spiegelman D, et al. Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy. AIDS 1999; 13 (11): 1351-7
34. 34. Smith K, Germain M, Decker C, et al. Increased soft tissue in the posterior cervical and upper back area of patients on HIV-1 protease inhibitors. J Cutan Med Surg 1999; 3 (4): 211-7
35. 35. Stricker RB, Goldberg B. Fat accumulation and HIV-1 protease inhibitors [letter]. Lancet 1998; 352 (9137): 1392
36. 36. Saint-Marc T, Touraine JL. 'Buffalo hump' in HIV-1 infection. Lancet 1998; 352 (9124): 319-20
37. 37. Roth VR, Kravcik S, Angel JB. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 1998; 27 (1): 65-7
38. 38. Engelson ES, Kotler DP, Tan Y, et al. Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am J Clin Nutr 1999; 69 (6): 1162-9
39. 39. Fischer T, Schworer H, Ramadori G. Benign symmetrical lipomatosis ('peripheral lipodystrophy') during antiretroviral therapy of HIV infection. Dtsch Med Wochenschr 1998; 123 (50): 1512-6
40. 40. Hengel RL, Watts NB, Lennox JL. Benign symmetric lipomatosis associated with protease inhibitors [letter]. Lancet 1997; 350: 1596
41. 41. Jaquet D, Khallouf E, Levy-Marchal C, et al. Extremely low values of serum leptin in children with congenital generalized lipoatrophy. Eur J Endocrinol 1999; 140 (1): 107-9
42. 42. Garg A, Wilson R, Barnes R, et al. A gene for congenital generalized lipodystrophy maps to human chromosome 9q34. J Clin Endocrinol Metab 1999; 84 (9): 3390-4
43. 43. Chen D, Garg A. Monogenic disorders of obesity and body fat distribution. J Lipid Res 1999; 40 (10): 1735-46
44. 44. Jackson SN, Howlett TA, McNally PG, et al. Dunnigan-Köbberling syndrome: an autosomal dominant form of partial lipodystrophy. QJM 1997; 90 (1): 27-36
45. 45. Köbberling J, Dunnigan MG. Familial partial lipodystrophy: two types of an X linked dominant syndrome, lethal in the hemizygous state. J Med Genet 1986; 23 (2): 120-7
46. 46. Pardini VC, Victoria IM, Rocha SM, et al. Leptin levels, beta-cell function, and insulin sensitivity in families with congenital and acquired generalized lipoatropic diabetes. J Clin Endocrinol Metab 1998; 83 (2): 503-8
47. 47. Shackelton S, Llyod DJ, Jackson SN, et al. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet 2000; 24 (2): 153-56
48. 48. Hubler A, Abendroth K, Keiner T, et al. Dysregulation of insulin-like growth factors in a case of generalized acquired lipoatrophic diabetes mellitus (Lawrence Syndrome) connected with autoantibodies against adipocyte membranes. Exp Clin Endocrinol Diabetes 1998; 106 (1): 79-84
49. 49. Spranger S, Spranger M, Tasman AJ, et al. Barraquer-Simons syndrome (with sensorineural deafness): a contribution to the differential diagnosis of lipodystrophy syndromes. Am J Med Genet 1997; 71 (4): 397-400
50. 50. Seip M, Trygstad O. Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr 1996; 413 Suppl.: 2-28
51. 51. Levy Y, George J, Yona E, et al. Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon. Immunol Res 1998; 18 (1): 55-60
52. 52. Williamson K, Reboli AC, Manders SM. Protease inhibitor-induced lipodystrophy. J Am Acad Dermatol 1999; 40 (4): 635-6
53. 53. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353 (9170): 2093-9
54. 54. Kotler DP, Rosenbaum K, Wang J, et al. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20 (3): 228-37
55. 55. Kotler DP, Thea DM, Heo M, et al. Relative influences of sex, race, environment, and HIV infection on body composition in adults. Am J Clin Nutr 1999; 69 (3): 432-9
56. 56. Madge S, Kinloch-de-Loes S, Mercey D, et al. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS 1999; 13 (6): 735-7
57. 57. Saint-Marc T, Touraine JL. Reversibility of peripheral fat wasting (lipatrophy) on stopping stavudine therapy [abstract no. 24]. Antiviral Therapy 1999; 4 Suppl. 2: 45-6
58. 58. Mallal S, John M, Moore C, et al. Protease inhibitors and nucleoside analogue reverse transcriptase inhibitors interact to cause subcutaneous fat wasting in patients with HIV infection [abstract no. 19]. Antiviral Therapy 1999; 4 Suppl. 2: 42-3
59. 59. Galli M, Ridolfo AL, Gervasconi C, et al. Incidence of fat tissue abnormalities in protease inhibitor-naive patients treated with NRTI combinations [abstract no. 20]. Antiviral Therapy 1999; 4 Suppl. 2: 43-4
60. 60. Mercie P, Tchamgoue S, Dabis F, et al. Lipodystrophy in HIV-1 infected patients [letter]. Lancet 1999; 354 (9181): 867-8
61. 61. Carr A, Miller J, Law M, et al. A syndrome of lipodystrophy (LD), lactat acidaemia and liver dysfunction associated with HIV nucleoside analogue reverse transcriptase inhibitor therapy: contribution to PI-related LD syndrome [abstract no. 11]. Antiviral Therapy 1999; 4 Suppl. 2: 33-4
62. 62. Abate N, Garg A. Heterogeneity in adipose tissue metabolism: causes, implications and management of regional adiposity. Prog Lipid Res 1995; 34: 53-70
63. 63. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev 1994; 74: 761-811
64. 64. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13 (10): 63F-70F
65. 65. Churchill DR, Pym AS, Babiker AG, et al. Hyperlipidaemia following treatment with protease inhibitors in patients with HIV-1 infection. Br J Clin Pharmacol 1998; 46 (5): 518-9
66. 66. Schmidt HH-J, Behrens G, Genschel J, et al. Lipid evaluation in HIV-1 positive patients treated with protease inhibitors. Antiviral Ther 1999; 4: 163-70
67. 67. Echevarria KL, Hardin TC, Smith JA. Hyperlipidemia associated with protease inhibitor therapy. Ann Pharmacother 1999; 33 (7-8): 859-63
68. 68. Meyer L, Rabaud C, Ziegler O, et al. Protease inhibitors, diabetes mellitus and blood lipids. Diabetes Metab 1998; 24 (6): 547-9
69. 69. Périard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 1999; 100 (7): 700-5
70. 70. Segerer S, Bogner JR, Walli R, et al. Hyperlipidemia under treatment with proteinase inhibitors. Infection 1999; 27 (2): 77-81
71. 71. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998; 12 (15): 167F-73F
72. 72. Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. AIDS 1997; 11 (7): 938-9
73. 73. Rozenbaum W, Gharakhanian, Salhi Y, et al. Clinical and laboratory characteristics of lipodystrophy in a French cohort of HIV-infected patients treated with protease inhibitors [abstract no. 12]. Antiviral Ther 1999; 4 Suppl. 2: 34
74. 74. Schmitz M, Michl G, Walli R, et al. Increased Apo B synthesis and defective delipidation of triglyceride-rich VLDL are potentially mechanisms of ART-associated dyslipidaemia [abstract no. 47]. Antiviral Ther 1999; 4 Suppl. 2: 59-60
75. 75. Behrens G, Schmidt HH-J, Stoll M, et al. ApoE genotype and protease-inhibitor-associated hyperlipidaemia [letter]. Lancet 1999; 354: 76
76. 76. Di Perri G, Del Bravo P, Concia E. HIV-protease inhibitors. N Engl J Med 1998; 339: 773-4
77. 77. McBride M, Chin MT, Lee SM, et al. Lipid lowering therapy in patients with HIV infection. Lancet 1998; 352 (9142): 1782-3
78. 78. Yarasheski KE, Tebas P, Marin D, et al. Heparin-releaseable lipoprotein lipase activity is reduced in HIV PI-associated hypertriglyceridaemia [abstract no. 70]. Antiviral Ther 1999; 4 Suppl. 2: 72-3
79. 79. Baril L, Idhammou, Beucler I, et al. Are the decreased lipolytic enzyme activities responsible for the hypertriglyceridemie in-PI treated patients [abstract no. 664] Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago (IL), 192
80. 80. Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and postheparin lipase activities in normal subjects. AIDS 2000; 14: 51-7
81. 81. Zangerle R, Sarcletti M, Gallati H, et al. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation J Acquir Immune Defic Syndr 1994; 7 (11): 1149-56
82. 82. Christeff N, Lortholary O, Casassus P, et al. Serum lipid concentration with reference to the clinical and immunological status of HIV infected men. Ann Med Intern 1995; 146 (7): 490-5
83. 83. Grunfeld C, Kotler DP, Hamadeh R, et al. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989; 86: 27-31
84. 84. Grunfeld C, Kotler DP, Shigenga JK, et al. Circulating interferon alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991; 90: 154-62
85. 85. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocr Metab 1992; 74: 1045-52
86. 86. Hellerstein MK, Grunfeld C, Wu K, et al. Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J Clin Endocrinol Metab 1993; 7: 559-65
87. 87. Shor-Posner G, Basit A, Lu Y, et al. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med 1993; 94 (5): 515-9
88. 88. Domingo P, Perez A, Torres OH, et al. Lipodystrophy in HIV-1 infected patients [letter]. Lancet 1999; 354 (9181): 868
89. 89. SoRelle R. Vascular and lipid syndromes in selected HIV-infected patients. Circulation 1998; 9: 829-30
90. 90. Eriksson U, Opravil M, Amann FW, et al. Is treatment with ritonavir a risk factor for myocardial infarction in HIV-infected patients? [letter] AIDS 1998; 12 (15): 2079-80
91. 91. Gallet B, Pulik M, Genet P, et al. Vascular complications associated with use of HIV protease inhibitors [letter]. Lancet 1998; 351 (9120): 1958-9
92. 92. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors [letter]. Lancet 1998; 351 (9112): 1328
93. 93. Laurence J. Vascular complications associated with use of HIV protease inhibitors [letter]. Lancet 1998; 351 (9120): 1960
94. 94. Vittecoq D, Escaut L, Monsuez JJ. Vascular complications associated with use of HIV protease inhibitors [letter]. Lancet 1998; 351 (9120): 1959
95. 95. Flynn TE, Bricker LA. Myocardial infarction in HIV-infected men receiving protease inhibitors [letter]. Ann Intern Med 1999; 131: 548
96. 96. Jutte A, Schwenk A, Franzen C, et al. Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment [letter]. AIDS 1999; 13: 1796-7
97. 97. Sullivan AK, Nelson MR, Moyle GJ. Coronary artery disease occurring with protease inhibitor therapy [letter]. Int J Std Aids 1998; 9: 711-2
98. 98. Meyer D, Behrens G, Schmidt RE, et al. Osteonecrosis of the femoral head in patients receiving HIV protease inhibitors [letter]. AIDS 1999; 13: 1147-8
99. 99. Johns DG, Gill MJ. Avascular necrosis in HIV infection [letter]. AIDS 1999; 13: 1997-8
100. 100. Timpone J, Fluhme D, Nascone J, et al. Avascular necrosis in HIV+ patients: a potential link to protease inhibitors [abstract no. 680]. Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago (IL), 195
101. 101. Yarasheski KE, Tebas P, Sigmund C, et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr 1999; 21 (3): 209-16
102. 102. Mauss S, Wolf E, Jaeger H. Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors [letter]. Ann Intern Med 1999; 130 (2): 162-3
103. 103. Vigouroux C, Gharakhanian S, Salhi Y, et al. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy. Diabetes Metab 1999; 25 (3): 225-32
104. 104. Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of protease inhibitor [letter]. Ann Intern Med 1997; 127 (10): 948
105. 105. Lee EC, Walmsley S, Fantus IG. New-onset diabetes mellitus associated with protease inhibitor therapy in an HIV-positive patient: case report and review. CMAJ 1999; 161 (2): 161-4
106. 106. Chronister CL, Gurwood AS. Type 2 diabetes in association with HIV-1 protease inhibitors in HIV-infected patients. J Am Optom Assoc 1998; 69 (11): 695-8
107. 107. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 1997; 127 (10): 947
108. 108. Mulligan K, Tai VW, Algren H, et al. Evidence of unique metabolic effects of protease inhibitors [abstract no. 414]. Program and Abstracts of the 5th Conference on Retrovirus and Opportunistic Infections; 1998 Feb 1-5; Chicago (IL), 321
109. 109. Dube MP, Johnson DL, Currier JS, et al. Protease inhibitor-associated hyperglycemia. Lancet 1997; 350: 713-4
110. 110. Besson C, Jubault V, Viard JP, et al. Ketoacidosis associated with protease inhibitor therapy. AIDS 1998; 12 (11): 1399-400
111. 111. Danoff A, Ling WLW. Protease inhibitors do not interfere with prohormone processing [letter]. Ann Intern Med 2000; 132: 330
112. 112. Hommes MJ, Romijn JA, Endert E, et al. Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism 1991; 40 (6): 651-6
113. 113. Shikuma CM, Waslien C, McKeague J, et al. Fasting hyperinsulinemia and increased waist-to-hip ratios in non-wasting individuals with AIDS. AIDS 1999; 13 (11): 1359-65
114. 114. Hadigan C, Miller K, Corcoran C, et al. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999; 84 (6): 1932-7
115. 115. Renard E, Fabre J, Paris F, et al. Syndrome of body fat redistribution in HIV-1-infected patients: relationships to cortisol and catecholamines. Clin Endocrinol 1999; 51 (2): 223-30
116. 116. Yanovski JA, Miller KD, Kino T, et al. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab 1999; 84 (6): 1925-31
117. 117. Christeff N, Melchior J-C, de Truchis P, et al. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. AIDS 1999; 13: 2251-60
118. 118. Grinspoon S, Corcoran C, Miller K, et al. Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab 1997; 82 (5): 1332-7
119. 119. Ockenga J, Widjaja A, Holtmannspötter M, et al. Bound leptin is regulated by TNF-α in HIV infected patients. A potential mediator of wasting [letter]. AIDS 1998; 12 (16): 2233-5
120. 120. Tracey KJ. The acute and chronic pathophysiological effects of TNF: mediation of septic shock and wasting (cachexia). In: Beutler B, editor. Tumor necrosis factors: the molecules and their emerging role in medicine. New York (NY): Raven Press, 1992: 255-73
121. 121. Corcoran C, Grinspoon S. Treatments for wasting in patients with the acquired immunodeficiency syndrome. N Engl J Med 1999; 340 (22): 1740-50
122. 122. Martinez E, Casamitjana R, Conget I, et al. Protease inhibitor-associated hyperinsulinaemia. AIDS 1998; 12 (15): 2077-9
123. 123. Carr A, Samaras K, Chisholm DJ, et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351 (9119): 1881-3
124. 124. Domingo P, Matias-Guiu X, Pujol RM, et al. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS 1999; 13: 2261-7
125. 125. Stevens GJ, Chen M, Gecko R, et al. Investigations into the proposed mechanisms of HIV-associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance [abstract no. 29]. Antiviral Ther 1999; 4 Suppl. 2: 49
126. 126. Gagnon AM, Angel JB, Sorisky A. Protease inhibitors and adipocytes differentiation in cell culture [letter]. Lancet 1998; 352 (9133): 1032
127. 127. Rohlmann A, Gotthardt M, Hammer RE, et al. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest 1998; 101 (3): 689-95
128. 128. Lenhard JM, Weiel JE, Paulik MA, et al. Indinavir enhances retinoic acid signaling: nelfinavir, saquinavir, and ritonavir inhibit retinoid effect in vitro [abstract 665]. Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago (IL), 193
129. 129. Lenhard JM, Weiel JE, Paulik MA, et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro [abstract 666]. Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago (IL), 193
130. 130. Lenhard JM, Furfine E, Paulik MA, et al. Effect of HIV protease inhibitors on in vitro adipogenesis and in vivo fat deposistion [abstract no. 1]. Antiviral Ther 1999; 4 Suppl. 2: 7131.
131. Wentworth JM, Burris TP, Chatterjee VK. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARγ/RXR heterodimer. J Endocrinol 2000; 164 (2): 7R-10R
132. 132. Brinkman K, ter Hofstede HJ, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12 (14): 1735-44
133. 133. Brinkman K, Smeitink JA, Romijn JA, et al. Mitochondrial toxicity induced by nucleosid-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354 (9184): 1112-5
134. 134. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995; 1 (5): 417-22
135. 135. Aldeen T, Wells C, Hay P, et al. Lipodystrophy associated with nevirapine-containing antiretroviral therapies [letter]. AIDS 1999; 13 (7): 865-7
136. 136. Daucourt V, Thiebaut R, Mercie P, et al. Prevalence of lipodystrophy and relation with clinical, anthropometric data and treatment, Aquitaine Chohort, 1999 [abstract no. 16]. Antiviral Ther 1999; 4 Suppl. 2: 40-1
137. 137. Polo R, Verdejo J, Martinez S, et al. Contribution of NRTIs combination on lipodystrophy and impact of therapy switching [abstract no. 67]. Antiviral Therapy 1999; 4 Suppl. 2: 71
138. 138. Martinez E, Conget I, Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13 (7): 805-10
139. 139. Ruiz L, Bonjoch A, Paredes R, et al. A multi-center, randomized, open-labled, comparative trail of the clinical benefit of switching the protease inhibitor by Nevirapine (NVP) in HAART-experienced patients suffering lipodystrophy [abstract no. 31]. Antiviral Ther 1999; 4 Suppl. 2: 50
140. 140. Tebas P, Yarasheski K, Powderly WG, et al. A prospective open-label pilot trial of maintenance nevirapine-containing regimen in patients with undetectable viral loads on protease inhibitor regimens for at least 6 months [abstract no. 45]. Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections. 2000 Jan 30-Feb 2; San Francisco (CA), 83
141. 141. Moyle GJ, Baldwin C, Comitis S, et al. Changes in visceral adipose tissue and blood lipids in persons reporting fat redistribution syndrome switched from PI therapy to efavirenz [abstract no. 55]. Antiviral Ther 1999; 4 Suppl. 2: 64
142. 142. Rozenbaum W, Adda N, Ngyen T, et al. Prospective follow-up of a PI substitution for efavirenz in patients with HIV-related lipodystrophy syndrome [abstract no. 68]. Antiviral Therapy 1999; 4 Suppl. 2: 71-2
143. 143. Polo R, Verdejo J, Gonzalez-Munoz M, et al. Switch to AZT plus 3TC improves lipodystrophy in the presence of protease inhibitors 8 [abstract no. 1306]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco (CA), 504
144. 144. Saint-Marc T, Touraine JL. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS 1999; 13: 2188-9
145. 145. Mulligan K, Grunfeld C, Hellerstein MK, et al. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. Clin Endocrinol Metab 1993; 77 (4): 956-62
146. 146. Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting: a randomized, placebo-controlled trial. Ann Intern Med 1996; 125: 873-82
147. 147. Wanke C, Gerrior J, Kantaros J, et al. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 1999; 13: 2099-103
148. 148. Torres R. Treatment of dorsocervical fat pads and truncal adiposity with serostim (recombinant human growth hormone] in patients with aids maintained on HAART [abstract no. 32164]. Abstracts of the 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 553
149. 149. Kotler DP, Rosenbaum KR, Wang J, et al. Alterations in body fat distribution in HIV-infected men and women [abstract no. 32173]. Abstracts of the 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 554-5
150. 150. Mauss S, Wolf E, Jaeger H. Reversal of protease inhibitor-related visceral abdominal fat accumulation with recombinant human growth hormone [letter]. Ann Intern Med 1999 Aug 17; 131 (4): 313-4
151. 151. Knopp R. Drug treatment of lipid disorders. N Engl J Med 1999; 341 (7): 489-511
152. 152. Fichtenbaum C, Gerber J, Rosenkranz S, et al. Pharmacokinetic interaction between protease inhibitors and selected HMG-CoA reductase inhibitors [abstract no. LB6]. Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco (CA), 236
153. 153. Henry K, Melroe H, Huebsch J, et al. Atorvastatin and gemfibrazol for protease-inhibitor-related lipid abnormalities. Lancet 1998; 352: 1031-2
154. 154. Hewitt RG, Shelton MJ, Esch LD. Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients. AIDS 1999; 13 (7): 868-9
155. 155. Roubenoff R, Weiss L, McDermott A, et al. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS 1999; 13 (11): 1373-5
156. 156. Roubenoff R, McDermott A, Weiss L, et al. Short-term progressive resistance training increases strength and lean body mass in adults infected with human immunodeficiency virus. AIDS 1999; 13: 231-9
157. 157. Yarasheski KE, Tebas P, Stanerson B, et al. Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy. [abstract no. 54]. Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco (CA), 85
158. 158. Mahler RJ, Adler ML. Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment. J Clin Endocrinol Metab 1999; 84 (4): 1165-71
159. 159. Goebel FD, Walli R. ART-associated insulin resistence: frequency, potential causes and possible therapeutic interventions [abstract no. 5]. Antiviral Ther 1999; 4 Suppl. 2: 13
160. 160. Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy [letter]. AIDS 1999; 13 (8): 1000-2
161. 161. Ponce-de-Leon S, Iglesias M, Ceballos J, et al. Liposuction for protease-inhibitor-associated lipodystrophy [letter]. Lancet 1999; 353 (9160): 124
162. 162. Wolfort FG, Cetrulo CL, Nevarre DR. Suction-assisted lipectomy for lipodystrophy syndromes attributed to HIV-protease inhibitor use. Plast Reconstr Surg 1999; 104: 1814-20
163. 163. Meyer D, Behrens G, Heiken H, et al. Risk factors for atherosclerosis in protease inhibitor experienced HIV patients with vascular complications [abstract no. 809]. Abstracts of the 7th European Conference on Clinical Aspects and Treatment of HIV-Infection; 1999 Oct 23-27; Lisbon, 204